In vitro effect of different mediators of apoptosis on canine cranial and caudal cruciate ligament fibroblasts and its reversibility by pancaspase inhibitor zVAD.fmk.
Primary fibroblast cultures of canine cranial (CCL) and caudal (CaCL) cruciate ligaments were stimulated with different apoptosis inducers with or without preincubation of the pancaspase inhibitor zVAD.fmk. In contrast to CaCL fibroblasts, fibroblasts from CCL were significantly more susceptible to apoptosis inducers of the intrinsic pathway like doxorubicin, cisplatin and nitric oxide (NO)-donors and to Fas ligand (FasL), an apoptosis inducer of the death receptor pathway. Apoptotic response to staurosporine and the peroxynitrite donor GEA was similar in both ligament fibroblasts. Stimulation with dexamethasone or TNFα could not induce apoptosis in CCL and CaCL fibroblasts, in spite of present TNFR1 and TNFR2 receptors. zVAD.fmk was able to prevent apoptosis in up to 66% of CCL cells when treated with FasL, cisplatin or doxorubicin but it had no effect on NO or peroxynitrite induced apoptosis. In conclusion, differential susceptibility to apoptotic triggers like FasL or NO between cranial and caudal cruciate ligament fibroblasts in vitro may be a reflection of the different susceptibilities to degenerative rupture of the ligament. These findings indicate that a general caspase inhibition does not completely protect canine CCL cells from apoptosis.
Forterre
Simone
S
Division of Small Animal Surgery and Orthopedics, Vetsuisse Faculty Bern, Department of Clinical Veterinary Medicine, University of Bern, Länggassstrasse 3012 Bern, Switzerland. simone.forterre@kkh.unibe.ch
Zurbriggen
Andreas
A
Spreng
David
D
D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D049109:Cell Proliferation; D002478:Cells, Cultured; D002945:Cisplatin; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D003907:Dexamethasone; D004285:Dogs; D004317:Doxorubicin; D053222:Fas Ligand Protein; D005347:Fibroblasts / Q000187:drug effects* / Q000502:physiology*; D008022:Ligaments / Q000166:cytology*; D009569:Nitric Oxide; D030421:Peroxynitrous Acid; D014409:Tumor Necrosis Factor-alpha
D000590:Amino Acid Chloromethyl Ketones; D015853:Cysteine Proteinase Inhibitors; D053222:Fas Ligand Protein; D014409:Tumor Necrosis Factor-alpha; C096713:benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; D030421:Peroxynitrous Acid; D009569:Nitric Oxide; D003907:Dexamethasone; D004317:Doxorubicin; D002945:Cisplatin